Latest News by Industry
NEW YORK, Nov. 10, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. ("Oramed" or the "Company") (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today reported its financial results for the quarter ended September 30, 2022.
"We are pleased to share our quarterly report for the third quarter of 2022. We had a strong quarter filled with important milestones, including positive Phase 2 NASH data and initial positive results from our Phase 1 oral Covid-19 vaccine trial. Over the next few months, we look forward to sharing multiple milestones, most notably topline data from our first Phase 3 oral insulin trial expected in January," said Oramed Chief Executive Officer, Nadav Kidron. "Oramed remains in a strong financial position with approximately $160 million in cash and investments as of September 30, 2022, allowing us to continue advancing all aspects of our pipeline and giving us sufficient runway to complete our pivotal oral insulin (ORMD-0801) Phase 3 trials and advance us towards potential FDA approval."
Financial Results for the Three Month Period Ended September 30, 2022
Full financial tables are included below.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which is being evaluated in two pivotal Phase 3 studies and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule ( ORMD-0901 ).
For more information, please visit www.oramed.com.
Forward-looking statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss the potential development and timing of an oral COVID-19 vaccine, what our financial position is expected to allow us to achieve, our expectations to share multiple milestones, including topline data from our first Phase 3 oral insulin trial, the expected timing of results of our clinical trials, the expected timing and achievement of milestones and other anticipated future results. In addition, historic results of scientific research and clinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and finally that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed' s reports filed from time to time with the Securities and Exchange Commission.
Company Contact:
Zach Herschfus
+1-844-9-ORAMED
zach@oramed.com
FINANCIAL TABLES
ORAMED PHARMACEUTICALS INC.
INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS
U.S. Dollars in thousands (except share and per share data)
(UNAUDITED)
September 30,
December 31,
2022
2021
Assets
CURRENT ASSETS:
Cash and cash equivalents
$
33,196
$
27,456
Short-term deposits
121,119
111,077
Marketable securities
5,234
7,747
Prepaid expenses and other current assets
623
1,657
Total current assets
160,172
147,937
LONG-TERM ASSETS:
Long-term deposits
2
25,094
Long-term investments
2,700
-
Marketable securities
-
3,875
Amounts funded in respect of employee rights upon retirement
23
26
Property and equipment, net
535
388
Operating lease right-of-use assets
1,005
500
Total long-term assets
4,265
29,883
Total assets
$
164,437
$
177,820
Liabilities and stockholders' equity
CURRENT LIABILITIES:
Accounts payable, accrued expenses and other liabilities
$
4,205
$
4,535
Deferred revenues
2,022
2,703
Payable to related parties
70
-
Operating lease liabilities
228
130
Total current liabilities
6,525
7,368
LONG-TERM LIABILITIES:
Long-term deferred revenues
4,000
3,340
Employee rights upon retirement
21
22
Provision for uncertain tax position
11
11
Operating lease liabilities
672
370
Other liabilities
61
99
Total long-term liabilities
4,765
3,842
COMMITMENTS (note 2)
Equity
EQUITY ATTRIBUTABLE TO COMPANY'S STOCKHOLDERS:
Common stock, $0.012 par value (60,000,000 authorized shares; 39,113,236
and 38,158,792 shares issued and outstanding as of September 30, 2022
and December 31, 2021, respectively)
470
459
Additional paid-in capital
307,876
292,514
Accumulated deficit
(154,538)
(126,520)
Total stockholders' equity
153,808
166,453
Non-controlling interests
(661)
157
Total equity
153,147
166,610
Total liabilities and equity
$
164,437
$
177,820
ORAMED PHARMACEUTICALS INC.
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
U.S. Dollars in thousands (except share and per share data)
(UNAUDITED)
Nine months ended
Three months ended
September 30,
September 30,
September 30,
September 30,
2022
2021
2022
2021
REVENUES
$
2,022
2,022
$
682
682
RESEARCH AND DEVELOPMENT EXPENSES
20,362
15,452
5,347
6,086
SALES AND MARKETING EXPENSES
1,433
172
463
172
GENERAL AND ADMINISTRATIVE EXPENSES
11,085
4,937
3,061
1,909
OPERATING LOSS
30,858
18,539
8,189
7,485
FINANCIAL INCOME (EXPENSE), NET
1,930
1,031
1,036
(51)
LOSS BEFORE TAX EXPENSES
28,928
17,508
7,153
7,536
TAX EXPENSES
100
-
100
-
NET LOSS FOR THE PERIOD
$
29,028
17,508
$
7,253
7,536
NET LOSS ATTRIBUTABLE TO NON-
CONTROLLING INTERESTS
1,010
764
193
279
NET LOSS ATTRIBUTABLE TO STOCKHOLDERS
28,018
16,744
7,060
7,257
LOSS PER SHARE
BASIC AND DILUTED LOSS PER SHARE OF
COMMON STOCK
$
0.72
$
0.54
$
0.18
$
0.21
WEIGHTED AVERAGE NUMBER OF SHARES
OF COMMON STOCK USED IN
COMPUTING BASIC AND DILUTED LOSS
PER SHARE OF COMMON STOCK
38,856,514
31,097,270
39,100,231
34,539,487
ORAMED PHARMACEUTICALS INC.
INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
U.S. dollars in thousands
(UNAUDITED)
Nine months ended
September 30,
2022
2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
$
(29,028)
$
(17,508)
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation
41
69
Non-cash expense for acquired in-process research and development
-
1,040
Exchange differences and interest on deposits and held to maturity bonds
(933)
429
Changes in fair value of investments
494
(732)
Stock-based compensation
8,961
2,896
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
1,034
128
Accounts payable, accrued expenses and related parties
(330)
1,875
Net changes in operating lease
(105)
-
Deferred revenues
(21)
(2,022)
Liability for employee rights upon retirement
(1)
-
Other liabilities
32
(74)
Total net cash used in operating activities
(19,856)
(13,899)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of held to maturity securities
-
(8,593)
Purchase of short-term deposits
(111,500)
(6,000)
Investment in long-term deposits
-
(25,000)
Proceeds from short-term deposits
128,000
9,500
Proceeds from maturity of held to maturity securities
5,336
6,065
Long-term investments
(2,700)
-
Proceeds from sale of mutual funds
-
3,029
Funds in respect of employee rights upon retirement
3
-
Purchase of property and equipment
(188)
(55)
Total net cash provided by (used in) investing activities
18,951
(21,054)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock, net of issuance costs
7,345
74,743
Proceeds from exercise of warrants and options
42
21,496
Transaction with non-controlling interests
-
1,500
Tax withholdings related to stock-based compensation settlements
(783)
-
Total net cash provided by financing activities
6,604
97,739
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS
41
(3)
INCREASE IN CASH AND CASH EQUIVALENTS
5,740
62,783
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD
27,456
21,630
CASH AND CASH EQUIVALENTS AT END OF PERIOD
$
33,196
$
84,413
(A) SUPPLEMENTARY DISCLOSURE ON CASH FLOWS -
Interest received
$
906
$
505
(B) SUPPLEMENTARY DISCLOSURE ON CASH FLOWS -
Recognition of operating lease right of use assets and liabilities
$
678
$
-
(C) ASSET ACQUISITION TRANSACTION (see note 8) -
In-process research and development
-
1,040
Transaction with non-controlling interests
-
1,500
Additional paid in capital
-
(1,045)
Non-controlling interests
$
-
$
(1,495)
View original content: https://www.prnewswire.com/news-releases/oramed-reports-third-quarter-2022-financial-results-301674899.html
SOURCE Oramed Pharmaceuticals Inc.